Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03837756
Recruitment Status : Recruiting
First Posted : February 12, 2019
Last Update Posted : April 19, 2021
Sponsor:
Collaborators:
Aalborg University Hospital
Odense University Hospital
Rigshospitalet, Denmark
Hvidovre University Hospital
The Peter Doherty Institute for Infection and Immunity
University of Utah
Oslo University Hospital
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:
This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074 in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1 reservoir

Condition or disease Intervention/treatment Phase
HIV-1-infection Drug: Saline Drug: Lefitolimod Drug: 3BNC117 and 10-1074 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:

Participants will be randomized 1:1:1:1 in a blinded fashion to receive:

Arm A: Placebo and Placebo Arm B: Lefitolimod and Placebo Arm C: Placebo and 3BNC117+10-1074 Arm D: Lefitolimod and 3BNC117+10-1074

Masking: Double (Participant, Investigator)
Masking Description: The participant and all study personnel who directly interact with study participants are blinded to study arm designation.
Primary Purpose: Treatment
Official Title: Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial.
Actual Study Start Date : May 6, 2019
Estimated Primary Completion Date : July 1, 2022
Estimated Study Completion Date : February 28, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Placebo Comparator: Arm A: Placebo/Placebo
This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.
Drug: Saline
Placebo

Active Comparator: Arm B: Lefitolimod/Placebo
This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.
Drug: Saline
Placebo

Drug: Lefitolimod
A TLR9 agonist administered s.c. once weekly for 8 weeks.
Other Name: MGN1703

Active Comparator: Arm C: Placebo/3BNC117 + 10-1074
This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.
Drug: Saline
Placebo

Drug: 3BNC117 and 10-1074
Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Other Name: RUhumab-001 and RUhumab-002

Active Comparator: Arm D: Lefitolimod/3BNC117 + 10-1074
This arm will receive both Lefitolimod and 3BNC117 + 10-1074.
Drug: Lefitolimod
A TLR9 agonist administered s.c. once weekly for 8 weeks.
Other Name: MGN1703

Drug: 3BNC117 and 10-1074
Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Other Name: RUhumab-001 and RUhumab-002




Primary Outcome Measures :
  1. Time to re-initiation of cART during analytical treatment interruption (ATI) [ Time Frame: Up to 26 weeks. ]
    Time from date of cART cessation to the date of the last of three consecutive plasma HIV-1 RNA measurements >10,000 copies/mL, CD4 cell count <350 on two consecutive measurements, or end of ATI (i.e. 26 weeks after cessation of cART) - whichever comes first.


Secondary Outcome Measures :
  1. Safety and Tolerability assessment measured by AEs, Adverse Reactions (ARs), SAEs, [ Time Frame: Duration of the study ]
    Subject who receives at least one dose of the IMP(s) will be included in the evaluation for safety, measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs) and (SUSAR)

  2. Plasma HIV RNA doubling time [ Time Frame: Duration of ATI (up to 26 weeks) ]
    Plasma HIV RNA doubling time from first measurement >50 copies/mL to first measurement >1,000 copies/mL during the analytical treatment interruption (plasma HIV RNA measured by standard clinical assays, e.g. Cobas TaqMan; Lower limit of quantitation 20 copies/mL)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented HIV-1 infection
  • Adults age 18-65 years
  • On ART for a minimum of 18 months.
  • CD4+ T cell count >500 at screening
  • HIV-1 RNA plasma level of < 50 copies/mL by standard assays for at least 15 months (a single viral load measurement > 50 but < 500 copies/mL during this time period is allowable).
  • Able to give informed consent
  • Viral reservoir sensitivity to 3BNC117 and 10-1074. (Sensitivity of the viral reservoir to neutralization by 3BNC117 and 10-1074 will be tested following the screening visit (i.e. prior to randomization)).

Sensitivity of the viral reservoir to neutralization by 3BNC117 and 10-1074 will be tested following the screening visit (i.e. prior to enrollment and randomization). Isolated PBMCs will be analyzed using the PhenoSense HIV mAb Assay, Monogram Biosciences. The sensitivity of an individuals archieved proviruses to bNAb neutralization will be determined by the IC50 value of PBMC derived pseudovirus inhibition. Subjects that are considered sensitive to both 3BNC117 (IC90<=1.5 μg/mL) and 10-1074 (IC90<=2.0 μg/mL) AND MPI>97 AND fulfill the other inclusion/exclusion criteria will proceed to study enrolment and randomization.

If sensitivity cannot be determined by the PhenoSense HIVmAb Assay, participants will be screened for 3BNC117 and 10-1074 sensitivity using HIV env sequencing carried out in-house (Aarhus, Denmark). The method was originally established and validated by Rockefeller University that already has this method implemented. The method utilizes HIV-1 DNA envelope sequencing and a mathematical prediction binding algoritm of known binding sites of the antibodies. Based on the individual HIV env sequence, proviruses are categorized as "sensitive" or "resistant". Subjects that are determined to be sensitive to both 3BNC117 and 10-1074 (defined as at least 90% of known sequences sensitive to either bNAb) AND fulfill the other inclusion/exclusion criteria will proceed to study enrolment and randomization.

Exclusion Criteria:

  • Any significant acute medical illness requiring hospitalization in the past 4 weeks
  • Any evidence of an active AIDS-defining opportunistic infection
  • Any condition that, in the Investigator's opinion, will prevent adequate compliance with study therapy
  • The following laboratory values at screening, the values can be repeated within the screening period, but test results must be available before baseline (Day 0) and checked for eligibility: Hepatic transaminases (AST or ALT) ≥3 x upper limit of normal (ULN) // Serum total bilirubin ≥3 ULN // Estimated glomerular filtration rate (eGFR) ≤50 mL/min (based on serum creatinine) // Platelet count ≤100 x109/L // Absolute neutrophil count ≤1x109/L
  • Hepatitis B or C infection
  • History of: Malignancy, excluding non-melanoma skin cancers, or organ transplantation
  • Receipt of strong immunosuppressive or systemic chemotherapeutic agents within 28 days prior to study entry
  • Known resistance to >2 classes of ART
  • Known hypersensitivity to the components of lefitolimod, 3BNC117, 10-1074 or their analogues
  • Pre-existing autoimmune or antibody-mediated diseases
  • Women who are pregnant or breastfeeding, or unwilling/ unable to use an acceptable method of contraception (if of child bearing potential)
  • Males or females who are unwilling or unable to use barrier contraception during sexual intercourse until plasma HIV-1 RNA is undetectable using standard assays

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03837756


Contacts
Layout table for location contacts
Contact: Ole S Søgaard, MD PhD +45 78452842 olesoega@rm.dk
Contact: Jesper F Højen, MD +45 40459718 jephns@rm.dk

Locations
Layout table for location information
United States, Utah
Dept. of Internal Medicine, University of Utah Not yet recruiting
Salt Lake City, Utah, United States, 84132
Contact: Adam M Spivak, MD         
Australia
Alfred Hospital and Monash University Recruiting
Melbourne, Australia
Contact: Sharon Lewin, MD         
Contact: Thomas A Rasmussen, MD       thomas.rasmussen@unimelb.edu.au   
Denmark
Dept. of Infectious Diseases, Aalborg University Hospital Recruiting
Aalborg, Denmark, 9000
Contact: Henrik Nielsen, MD         
Dept. of Infectious Diseases, Aarhus University Hospital Recruiting
Aarhus, Denmark, 8200
Contact: Jesper D Gunst, MD    +45 40459815    jesdam@rm.dk   
Dept. of Infectious Diseases, Rigshospitalet Recruiting
Copenhagen, Denmark, 2100
Contact: Jan Gerstoft, MD         
Dept. of Infectious Diseases, Amager and Hvidovre Hospitals Recruiting
Hvidovre, Denmark, 2650
Contact: Thomas Benfield, MD         
Dept. of Infectious Diseases, Odense University Hospital Recruiting
Odense, Denmark, 5000
Contact: Isik S. Johansen, MD         
Norway
Oslo University Hospital Recruiting
Oslo, Norway
Contact: Dag Henrik Reikvam, MD PhD    +47 2211 9881    dagrei@ous-hf.no   
Sponsors and Collaborators
University of Aarhus
Aalborg University Hospital
Odense University Hospital
Rigshospitalet, Denmark
Hvidovre University Hospital
The Peter Doherty Institute for Infection and Immunity
University of Utah
Oslo University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Ole S Søgaard, MD PhD Aarhus University Hospital
Layout table for additonal information
Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT03837756    
Other Study ID Numbers: TITAN-001
2018-001165-16 ( EudraCT Number )
AGR-2016-8833 ( Other Grant/Funding Number: Gilead Sciences, Inc. )
First Posted: February 12, 2019    Key Record Dates
Last Update Posted: April 19, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan).
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Time Frame: Data will become available following publication of the specific dataset with no planned end date.
Access Criteria: Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposal should be addressed to olesoega@rm.dk

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection